Zura Bio Ltd

Zura Bio Ltd (Nasdaq: ZURA) is a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases that completed its SPAC business combination and began trading in 2023. The company filed an 8-K with the SEC on June 2, 2023, reflecting activity tied to its post-merger public company status. Zura Bio operates in the biotechnology and immunology sector, advancing a pipeline targeting conditions driven by immune dysregulation. The SPAC transaction provided Zura Bio with a public listing vehicle to fund its clinical development programs. For full filing history, deal terms, pipe details, and sponsor information on ZURA and hundreds of other SPAC transactions, sign up for complete data access at SpacDesk.